Objective-The ATP-binding cassette transporter A1 (ABCA1) protein maintains cellular cholesterol homeostasis in several different tissues. In the liver, ABCA1 is crucial for high-density lipoprotein biogenesis, and in the pancreas ABCA1 can regulate insulin secretion. In this study, our aim was to identify novel microRNAs that regulate ABCA1 expression in these tissues. Approach and Results-We combined multiple microRNA prediction programs to identify 8 microRNAs that potentially regulate ABCA1. A luciferase reporter assay demonstrated that 5 of these microRNAs (miR-148, miR-27, miR-144, miR-145, and miR-33a/33b) significantly repressed ABCA1 3′-untranslated region activity with miR-145 resulting in one of the larger decreases. In hepatic HepG2 cells, miR-145 can regulate both ABCA1 protein expression levels and cholesterol efflux function. In murine islets, an increase in miR-145 expression decreased ABCA1 protein expression, increased total islet cholesterol levels, and decreased glucose-stimulated insulin secretion. Inhibiting miR-145 produced the opposite effect of increasing ABCA1 protein levels and improving glucose-stimulated insulin secretion. Finally, increased glucose levels in media significantly decreased miR-145 levels in cultured pancreatic beta cells. These findings suggest that miR-145 is involved in glucose homeostasis and is regulated by glucose concentration. Conclusions-Our studies demonstrate that miR-145 regulates ABCA1 expression and function, and inhibiting this microRNA represents a novel strategy for increasing ABCA1 expression, promoting high-density lipoprotein biogenesis in the liver, and improving glucose-stimulated insulin secretion in islets. (Arterioscler Thromb Vasc Biol. 2013;33:2724-2732.)
M utations in both alleles of the ATP-binding cassette transporter A1 (ABCA1) gene results in Tangier disease, an autosomal recessive disorder whose clinical hallmark is the almost complete absence of high-density lipoprotein (HDL)-cholesterol in the plasma of affected individuals. [1] [2] [3] The ABCA1 protein is ubiquitously expressed in murine 4 and human 5 tissues. The function of ABCA1 is to remove cholesterol from cells and does so by effluxing free cholesterol to apolipoprotein A-I (apoA-I) protein acceptors. 6 Studies in animal models demonstrate the critical role of ABCA1 in cholesterol metabolism for different tissues. In the liver, ABCA1-mediated efflux of cholesterol to apoA-I generates nascent or immature HDL particles. 7 Targeted loss of hepatic ABCA1 in mice results in reduced levels of total and HDL-cholesterol by >80% compared with control mice. 8 Disruption of ABCA1 in macrophages increases the proinflammatory response to lipopolysaccharides, as well as increasing the development of atherosclerosis in hypercholesterolemic mouse models. 9, 10 In mice containing inactivation of ABCA1 in the central nervous system, structural and functional deficits are observed, including a reduction in the number of synaptic vesicles, attenuated locomotor activity, and a reduction in acoustic startle response. 11 ABCA1 in pancreatic β-cells functions to maintain islet cholesterol homeostasis and proper insulin secretion after glucose stimulation. 12 Human studies demonstrate that some carriers of heterozygous mutations in ABCA1 have impaired insulin secretion, 13 and individuals diagnosed with Tangier disease can manifest with diabetes mellitus. 14 ABCA1 expression is regulated by epigenetic, 15 transcriptional, 16 post-transcriptional, [17] [18] [19] [20] [21] [22] [23] [24] and post-translational 25 mechanisms. Potent transcriptional liver X receptor (LXR) agonists of ABCA1 exist; however, these agonists also activate genes involved in hepatic triglyceride synthesis, fatty acid synthesis, hypertriglyceridemia, and hepatic steatosis. 16 Proteins undergo post-transcriptional regulation through multiple mechanisms, including protein binding, 26 alternative polyadenylation sites, 27 and the binding of small noncoding microRNAs (miRNAs) to the 3′-untranslated regions (3′UTRs) of transcripts. 26 Protein translation is partly dependent on the length of the 3′UTR in mRNA. Regions longer than 1 kb decay much faster than shorter 3′UTRs, partly because of a greater number of miRNA binding sites present in long 3′UTRs. 28 ABCA1 has an exceptionally long 3′UTR at 3309 base pairs (bps). In comparison, the average length of a 3′UTR in a study of 1500 human genes was only 755 bp. 29 This suggests that multiple miRNAs regulate ABCA1. Indeed, several miRNAs have been validated recently to regulate ABCA1 expression and function. [17] [18] [19] [20] [21] [22] [23] [24] MiR-33a was the first miRNA demonstrated to regulate ABCA1 expression in hepatic cells and macrophages. 17, 19 Few miRNAs are exclusive to a given tissue, and only one third of all miRNAs demonstrate preferential tissue expression. 30 MiR-33a is ubiquitously expressed 17, 18 and it can regulate ABCA1 expression and function in multiple cell types. We recently demonstrated that miR-33a regulates ABCA1 expression, cholesterol levels, and glucose-stimulated insulin secretion in islets. 31 In this study, we identify miR-145 as a novel miRNA regulator of ABCA1 in both hepatic and pancreatic cell lines, as well as in pancreatic islets.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

ABCA1 Transcript Has Numerous Binding Sites for miRNAs
A luciferase reporter construct containing the 3′UTR (3309 bp) of human ABCA1 was transfected into murine (MIN6 pancreatic cells, 3T3L1 adipocytes) and human (HEK293 embryonic kidney, skin fibroblasts, HepG2 hepatocytes) cell lines, with activity measured 24 hours after transfection. Decreased activity was observed in all cell lines ( Figure I in the onlineonly Data Supplement) and suggests that the 3′UTR is a critical component in controlling ABCA1 expression levels.
We used an in silico approach to identify potential miR-NAs that could bind the 3′UTR of ABCA1. 32 The lack of definitive miRNA target recognition patterns means most bioinformatic prediction programs have a high proportion of false-positives. 33 Commonly used programs, such as TargetScan and PicTar, have a precision of ≈50% and sensitivity between 6% and 12%. 32 Prediction programs are composed of unique algorithms that identify miRNA targets based on different factors such as site conservation, nucleotide composition, and location of miRNA binding sites. 32 We used 5 programs (TargetScanHuman 5.2, PicTar, microRNA. org, miRDB, FindTar) to identify miRNA binding sites in the 3′UTR of ABCA1 ( Table I in the online-only Data  Supplement) . To narrow down the total number of potential miRNAs targeting ABCA1, we combined the results from these 5 programs. This approach can increase specificity but does so at a cost of decreased sensitivity. 32 We also limited the miRNAs we investigated to those known to be expressed in the liver because of the critical role of hepatic ABCA1 in HDL biogenesis. 8 By selecting miRNAs chosen by 4 of 5 programs, and those miRNAs known to be expressed in the liver, we identified 8 miRNAs that potentially regulate ABCA1: miR-17, miR-145, miR-19a, miR-96, miR-33a/33b, miR-27a, miR-148, and miR-144 (Table II in 
Five miRNAs Decrease ABCA1 Activity in a Reporter Assay
To identify the miRNAs that can regulate ABCA1, oligonucleotide mimics representing each of the 8 miRNAs were cotransfected with the ABCA1 3′UTR reporter construct into U343 cell lines. Five miRNAs demonstrated significant inhibition of luciferase activity: miR-148 by 16%, miR-27a by 20%, miR-144 by 25%, miR-145 by 28%, and miR-33a/33b by 52%/48% ( Figure 1A ). Studies by other groups have since validated miR-33a/33b, [17] [18] [19] miR-144, 22, 23 and miR-27a 24 as regulating ABCA1. Expression of miR-145 resulted in the second largest repression of activity after miR-33a. Two miR-145 binding sites are predicted in the 3′UTR of ABCA1, a site downstream of the stop codon (site 1, 109-115), and a site upstream of the poly A tail (site 2, 3114-3120; Figure  II in the online-only Data Supplement). Site-directed mutagenesis was performed on the 2 binding sites to identify which site(s) miR-145 binds to regulate ABCA1 ( Figure 1B ). Reporter constructs containing mutations to site 1 eliminated the inhibitory effect of miR-145 to the same extent as mutations to both sites (mutations to site 1 and mutations to site 2; Figure 1C ), suggesting that site 1 is the primary binding site for miR-145.
MiR-145 Regulates ABCA1 in HepG2 Cells
We focused on the regulation of ABCA1 by miR-145 for 2 reasons: (1) the overexpression of miR-145 resulted in the second largest repression of 3′UTR activity after miR-33a; and (2) the primary miR-145 binding site possesses features known to increase the efficacy of miRNA/mRNA target interactions. These features include a binding site ≥15 nucleotides away from the stop codon while also being located as far from the center of UTRs as possible. 34 Of all the binding sites for the 5 miRNAs identified in our reporter assay as regulating ABCA1, miR-145's primary binding site (site 1, 109-115) has a distance of >15 nucleotides from the stop codon while also being located furthest from the center of the ABCA1 3′UTR ( Figure II in the online-only Data Supplement).
To demonstrate that miR-145 can regulate ABCA1 in hepatic cells, we manipulated miR-145 expression in the HepG2 cell-line and assessed ABCA1 protein expression through immunoblotting studies and ABCA1 function through cholesterol efflux activity assays. Transfection of pre-miR-145 oligonucleotide mimics decreased ABCA1 protein levels ( Figure 2A ) and significantly reduced ABCA1 cholesterol efflux to apo A-I in HepG2 cells ( Figure 2B ). In all our experiments, scrambled control miRNA was used as a negative control, and miR-33a was used as a positive control. Measurement of miRNA expression levels after transfection of the mimics demonstrated that the effect of miR-145 on ABCA1 expression and function is specific to increased miR-145 expression, and not a result of changes in miR-33a expression ( Figure 2C and 2D ). Previous studies have suggested that miR-145 is cotranscribed with another miRNA, miR-143 that lies within 1.7 kilobases on chromosome 18. 35 We examined whether miR-143 could regulate ABCA1, but observed no changes to ABCA1 protein expression or cholesterol efflux function after overexpression of miR-143 in HepG2 cells ( Figure 2E and 2F). The specificity of miR-145 regulation on ABCA1 function was further demonstrated when we observed that miR-145* (passenger strand) does not decrease ABCA1 function ( Figure IIIA and IIIB in the online-only Data Supplement). To validate the findings from our luciferase reporter assay, we analyzed the effect of miR-17 on ABCA1 expression and function. Although miR-17 was 1 of the 8 miRNAs predicted to target ABCA1 in silico ( Table II in 
Combination of miR-33a and miR-145 Does Not Result in Additive or Synergistic Effects on ABCA1
The majority of miRNAs have subtle effects on their predicted targets. 36 A combination of miRNAs may additively or synergistically enhance the repressive effects over a single miRNA acting alone. 37 However, we found that the combination of miR-33a and miR-145 did not enhance repression of ABCA1 protein levels ( Figure 3A and 3B) or cholesterol efflux activity ( Figure 3C ) compared with either miRNA expressed singly. Inhibiting miR-145 using single-stranded RNA inhibitor sequences in HepG2 cells increased ABCA1 protein levels ( Figure 3D ) and increased cholesterol efflux activity by 29% ( Figure 3E ). Again we did not observe an enhanced effect on ABCA1 protein expression or efflux function when combining the 2 miRNA inhibitors compared with each inhibitor expressed independently. 
MiR-145 Regulates ABCA1 Expression in β-Cells and Islets
We generated adenoviruses expressing miR-33a, miR-145, along with their respective inhibitors. Transduction of HepG2 cells with adenoviruses resulted in similar effects on ABCA1 protein expression and cholesterol efflux activity as transfecting with their respective oligonucleotide counterparts ( Figure  VA and VB in the online-only Data Supplement). We previously demonstrated that miR-33a influences islet cell cholesterol content and islet function through ABCA1. 31 The identification of miR-145 expression in islets ( Figure To determine the effects of miR-145 on islet function, we used primary pancreatic islets isolated from mice. Murine primary islets were used rather than MIN6 cells because of the low levels of endogenous miR-145 in MIN6 cells ( Figure 4A) , the low basal levels of ABCA1 in MIN6 cells ( Figure VIIA in the online-only Data Supplement), and primary islets representing a more physiologically relevant assessment of islet cell function than the MIN6 cell line.
In primary islets, adenoviral-miR-145 expression decreased ABCA1 protein levels, whereas adenoviral-inhibitors to miR-145 increased ABCA1 expression ( Figure 4B and 4C) . In a cell, miRNAs range in expression from <1 copy to >10 000 copies. 38 Expression analysis by reverse transcription-quantitative polymerase chain reaction (TaqMan) revealed that miR-145 is expressed in multiple human ( Figure VIA in the online-only Data Supplement) and murine ( Figure VIB in the online-only Data Supplement) tissues. The regulation of miRNA targets is partially dependent on the expression level of miRNA in cells and tissues, and high miRNA expression is expected to be associated with enhanced suppression of target transcripts.
We compared the concentrations of miR-145 with miR-33a in murine liver and islets, as well as in MIN6 cells, by absolute quantification reverse transcription-quantitative polymerase chain reaction using the standard curve method ( Figure  VIII in the online-only Data Supplement). After correcting for primer efficiencies, we found miR-145 and miR-33a to be equally expressed in murine liver and islets ( Figure 4A ). Based on their expression profiles, we expect that inhibiting miR-145 in islets could lead to similar increases in ABCA1 protein expression as inhibiting miR-33a. Indeed, we found that in primary murine islets, inhibiting miR-145 resulted in equivalent increases to ABCA1 protein levels as inhibiting 
MiR-145 Regulates Total Cholesterol Content and Insulin Secretion in Murine Pancreatic Islets
We next investigated the effects of miR-145 on islet cell function. Overexpressing miR-145 resulted in a significant increase to total islet cholesterol content ( Figure 5A ). However, changes in cholesterol were not observed after miR-145 inhibition ( Figure 5A ). This is similar to what we observed after miR-33a inhibition in islets in a previous study. 31 In both cases, we speculate that inhibiting miR-145 or miR-33a results in localized reductions in cholesterol levels; however, these localized decreases are not detected in our total islet cholesterol measurements. In islets from mice lacking ABCA1 in the β-cell (ABCA1 β-cell −/− ), no changes were observed in total cholesterol after miR-145 inhibition ( Figure  5B ). However, in a mouse model of hypercholesterolemia and reduced islet ABCA1 expression (ApoE −/− ), 39 primary islets treated with miR-145 inhibitors showed a significant reduction in total cholesterol content ( Figure 5B ). MiR-145 also influenced islet function, as adenoviral overexpression of miR-145 significantly decreased glucose-stimulated (20 mmol/L) insulin secretion ( Figure 5C ), whereas adenoviral inhibition of miR-145 significantly increased glucose-stimulated (20 mmol/L) insulin secretion ( Figure 5D ). These findings support a critical role for the regulation of insulin secretion and islet function by miR-145.
Expression of miR-145 Is Regulated by Glucose Levels
We next investigated the regulation of miR-145 in the context of islet β-cell function. Previous studies demonstrated that miR-145 expression is induced after serum starvation in human colorectal carcinoma-116 and -8 cell lines. 40 We verified this in cultured pancreatic β-cells where we found that reduced serum levels in cell culture media increased miR-145 expression levels by 38% in MIN6 cells ( Figure IX in the online-only Data Supplement). We next investigated whether glucose levels could affect miR-145 expression. High glucose levels in cell culture media (25 mmol/L) resulted in a 35% decrease in miR-145 levels in MIN6 cells ( Figure 6A ). The effect of glucose on miR-33a was not as significant as the effects of glucose on miR-145 levels ( Figure 6B ). This finding suggests that miR-145 has a role in the glucose homeostatic pathway.
Discussion
Post-transcriptional regulation of protein expression occurs when miRNAs bind sites in the 3′UTR to inhibit translation or initiate mRNA degradation. ABCA1 contains a longer than average 3′UTR with multiple predicted and validated binding sites for miRNAs. In this study, we identify miR-145 as a novel regulator of ABCA1 in hepatic and pancreatic cell lines, and in pancreatic islets. By combining the results from 5 bioinformatics programs and identifying those miRNAs expressed in the liver, 8 potential miRNA regulators of ABCA1 were found. This included several miRNAs recently validated as regulating ABCA1 expression and function. [17] [18] [19] [22] [23] [24] A luciferase reporter assay demonstrated that 5 of the 8 miRNAs decreased ABCA1 activity including miR-145. The features of the primary miR-145 binding site (site 1, 109-115; Figure II in the online-only Data Supplement) support a regulatory role for ABCA1 expression. These features include a location rich in AU nucleotides, being situated away from the middle of UTRs where occlusive interactions can form, being ≥15 nucleotides away from the stop codon where interference from bound ribosomes arises, and a location rich with binding sites for a variety of different miRNAs. 34, 41 In HepG2 cells, a cell-line relevant for HDL biogenesis, miR-145 was found to regulate ABCA1 expression and function. In contrast, miR-143 and miR-145* did not affect ABCA1 activity, which demonstrates the specific regulation of ABCA1 by miR-145. MiR-143 was previously thought to be cotranscribed with miR-145 as part of a cardiovascularspecific miRNA cluster. 35 MiR-145* is the complementary sequence (passenger strand) to miR-145 in the miRNA/ miRNA* duplex that is generated when the RNAseIII enzyme Dicer processes pre-miRNAs. 42 The addition of exogenous miR-145* may even inhibit miR-145 regulation of ABCA1 by binding endogenous miR-145 and inhibiting its ability to target and reduce ABCA1 expression and function.
Our studies demonstrated that miR-33a mimics decreased ABCA1 protein levels and efflux activity more than miR-145 mimics in HepG2 cells. Their effect may be explained by a unique feature of the miR-33a binding sites found in ABCA1. Multiple binding sites increase the likelihood that a miRNA regulates a target mRNA. Although miR-145 has 2 binding sites in the 3′UTR of ABCA1 at position 109 to 115 and 3114 to 3120 (TargetScanHuman 5.2), miR-33a has 3 binding sites at positions 134 to 140, 139 to 145, and 149 to 155 (TargetScanHuman 5.2) downstream of the ABCA1 stop codon. Binding sites can produce a synergistic effect when neighboring one another compared with 2 distant sites. 34 Although miR-33a has 3 binding sites within 20 bp of one Most biological processes are thought to involve multiple members of a miRNA family, unrelated miRNAs, or a combination of miRNAs and transcription factors. 36 A slight additive effect between miR-758 and miR-33a on ABCA1 regulation has been reported previously. 20 We investigated the possibility that miR-145 and miR-33a could cooperate to enhance the regulation of ABCA1 in HepG2 cells. No significant difference in ABCA1 protein levels or function was observed after the combined expression of both miRNAs compared with either miRNA expressed alone. The lack of a combined effect by miR-145 and miR-33a may be because of an upper threshold in the regulation of transcripts by miRNAs or mechanisms that limit the effect of miRNAs on a gene.
MiR-145 is expressed in several different tissues and cell lines, 35, [43] [44] [45] including in murine pancreatic islets ( Figure 4A ). ABCA1 plays a key role in maintaining islet cholesterol homeostasis and ensuring proper β-cell function, 12 and we previously demonstrated that miR-33a can affect islet cholesterol homeostasis and mediate β-cell insulin secretion through the regulation of ABCA1. 31 In this study, we reveal a similar regulatory function for miR-145, demonstrating that in primary islets miR-145 regulates ABCA1 expression and insulin secretion. Inhibiting miR-145 in islets resulted in similar increases to ABCA1 protein expression as inhibiting miR-33a. Our studies demonstrate inhibiting miR-145 as a novel strategy to increase ABCA1 expression and function in islets.
The physiological role of miR-145 regulation of ABCA1 may be a response to the presence of nutrients. Human colorectal carcinoma cells grown without serum show a significant elevation of miR-145 expression. 40 We found a similar increase in miR-145 expression in MIN6 β-cells grown in media containing low serum. MiR-145 plays a major role in the growth and differentiation of cells, and studies have validated several transcription factors and cell cycle genes as targets of miR-145. Increased levels of miR-145 decreases cell growth, induces cell cycle arrest, increases apoptosis, and decreases cell migration. 43, 45 Because of our demonstration that miR-145 has a regulatory role over islet function, we investigated the effects of glucose on miR-145 expression levels in cultured pancreatic β-cells. We observed a decrease in miR-145 expression when MIN6 cells were exposed to high glucose levels in the media after 48 hours. We propose a mechanism where increased glucose levels leads to decreased miR-145 levels in β-cells. This decreased expression of miR-145 can then increase the expression of miR-145 targeted genes involved in insulin secretion such as ABCA1. Figure 5 . MiR-145 regulates total cholesterol levels and glucosestimulated insulin secretion in murine pancreatic islets. A, Total cholesterol levels in primary islets transduced with adenovirus control (Cont) and adenovirus miR-145 or adenovirus control (Cont) and adenovirus miR-145 inhibitor at a MOI=100 for 48 hours. All cholesterol values are normalized to protein concentration (n=5). B, Total cholesterol levels in pancreatic islets isolated from mice with β-cell-specific deletion of ATP-binding cassette transporter A1 (ABCA1; ABCA1 β-cell −/− ), and mice with a global deletion of apolipoprotein E (ApoE −/− ) transduced with adenovirus control (Cont) and adenovirus miR-145 inhibitor at a MOI=100 for 48 hours. All cholesterol values are normalized to protein concentration (n=4-6). C, Glucose-stimulated (20 mmol/L) insulin secretion in pancreatic islets isolated from wild-type mice after transduction with adenovirus control (Cont) and adenovirus miR-145 at a MOI=100 for 48 hours. All insulin secretion values are normalized to total islet DNA concentration (n=6). D, Glucosestimulated (20 mmol/L) insulin secretion in primary pancreatic islet cells isolated from wild-type mice transduced with adenovirus control (Cont) and adenovirus miR-145 inhibitor at a MOI=100 for 48 hours. All insulin secretion values are normalized to total islet cell DNA concentration (n=7). All data are expressed as the mean±SD with the number of experiments performed indicated in parentheses. Significance is set at P≤0.05. These studies identify miR-145 as a novel post-transcriptional regulator of ABCA1 in both hepatic and pancreatic cells. ABCA1 in the liver is a critical determinant of plasma HDL levels. Future in vivo studies will be required to assess the impact of miR-145 on plasma HDL levels and atherosclerosis. Our studies also show that miR-145 is expressed in islets and that miR-145 regulates glucose-stimulated insulin secretion. Glucose levels also regulate miR-145 expression in β-cells. In conclusion, this study identifies inhibiting miR-145 as a novel strategy to increase ABCA1 expression, cholesterol efflux activity, and islet function.
